LORFAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LORFAN is a small-molecule injectable approved by Roche in 1956 with an unknown mechanism of action and indication profile. The product is nearing loss of exclusivity and represents a legacy asset in Roche's portfolio. Specific therapeutic indication and patient population cannot be determined from available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); commercial team likely in defend-and-divest mode with minimal growth headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LORFAN offers limited career development potential given zero linked job openings and approaching loss of exclusivity. Roles on this product are primarily focused on legacy asset management and managed decline rather than innovation and growth.
Field Sales RepresentativeBrand Manager
Worked on LORFAN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.